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Abstract
We introduce a Bayesian framework for estimating causal effects of binary and continuous treatments in
high-dimensional data. The proposed framework extends many of the existing semiparametric estimators
introduced in the causal inference literature to high-dimensional settings. Our approach has the following
features: it 1) considers semiparametric estimators that reduce model dependence; 2) introduces flexible
Bayesian priors for dimension reduction of the covariate space that accommodate nonlinearity; 3) can be
applied to any causal estimator that can be broadly defined as a function of the treatment and outcome
model (e.g. standard doubly robust estimator or the inverse probability weighted estimator); 4) provides
improved finite sample coverage compared to frequentist measures of uncertainty which rely on asymptotic
properties. We show that the posterior contraction rate of the proposed doubly robust estimator is the
product of the contraction rates of the treatment and outcome models. Via simulation we illustrate the
ability of the proposed estimators to flexibly estimate causal effects in high-dimensions, and show that it
performs well relative to existing approaches. Finally, we apply our proposed procedure to estimate the effect
of continuous environmental exposures. An R package implementing the proposed approach is available at
github.com/jantonelli111/DoublyRobustHD
1 Introduction
There has been a rapid growth in the interest of estimating the causal effect of a treatment (T ) on an outcome
(Y ) when the dimension of the covariate space (X) grows with the sample size. In high-dimensions, some form
of dimension reduction or variable selection is required, and most approaches utilize both the treatment and
outcome to reduce the dimension of the parameter space in a way that eliminates confounding bias. Recent
work has focused on utilizing doubly robust approaches to achieve
√
n consistent estimates of treatments
effects that provide uniformly valid inference (Belloni et al. , 2014; Farrell, 2015; Chernozhukov et al. , 2016).
In related work, Athey et al. (2018) achieve
√
n consistent estimation of treatment effects by combining
outcome regression models with weights that balance any remaining differences in covariates between treated
and control units. Other approaches have combined information from both the treatment and outcome to
improve finite sample performance of treatment effect estimation and confounder selection. Antonelli et al.
(2016) utilized the lasso (Tibshirani, 1996) to estimate a propensity and prognostic score, and showed that
matching on both quantities leads to doubly robust estimates of treatment effects. Ertefaie et al. (2018)
derived a new penalization estimator that incorporates information from both the treatment and outcome
to identify confounders. Shortreed & Ertefaie (2017) used the adaptive lasso to estimate propensity score
models that reduce shrinkage of coefficients for covariates also associated with the outcome. Antonelli et al.
(2017) used similar ideas but used information from the treatment model to reduce shrinkage of coefficients
in an outcome model. Finally, Hahn et al. (2016) utilized horseshoe priors on a re-parameterized outcome
and treatment model to tailor shrinkage of coefficients towards estimating treatment effects.
Nonlinear models have been adopted in the causal inference framework to flexibly estimate treatment
effects. Targeted maximum likelihood (TMLE) allows for the use of super learners or flexible machine learning
techniques to estimate functions of the covariates necessary to estimate treatment effects (Van Der Laan &
Rubin, 2006; Van der Laan & Rose, 2011). Recently, flexible Bayesian methods such as Bayesian additive
regression trees (BART) (Chipman et al. , 2010) have been utilized to flexibly model potential outcomes
to estimate treatment effects (Hill, 2011). While none of these approaches rely on modeling assumptions
in either the treatment or outcome model, they do not immediately extend to the high-dimensional regime
where p ≥ n.
In this paper we will utilize Bayesian methods to estimate propensity score or outcome regression models
in high-dimensions, and show how this leads to improved finite sample performance. Specifically, we propose
doubly robust estimators of treatment effects that incorporate nonparametric Bayesian methods to relax
modeling assumptions, coupled with sparsity inducing priors to reduce the dimension of the covariate space
in high-dimensional scenarios. We will show that - by calculating the posterior distribution of both the
treatment and outcome model parameters - we can obtain estimates and confidence intervals of a large class of
causal estimators such as the standard doubly robust estimator (Bang & Robins, 2005). We will estimate the
variance of the causal effect estimator by combining posterior samples with an efficient resampling procedure
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that will require only one MCMC run. This leads to confidence intervals that have good frequentist properties
in finite samples. Further, we build on previous results on doubly robust estimation in high dimensions
(Belloni et al. , 2014; Farrell, 2015) by proving a result that is analogous to a posterior contraction rate, and
show that our doubly robust estimator contracts at a rate that is the product of the posterior contraction
rates for the treatment and outcome models. Finally, our estimator is widely applicable, as it can be used
to estimate the causal effects of binary or continuous treatments in high-dimensional data.
2 Flexible doubly robust estimator
Throughout, we will assume that the observed data is (Xi, Ti, Yi) for i = 1 . . . n. T and Y are the treatment
and outcome of interest, respectively, while Xi is a p−dimensional vector of potential confounders. We will
be working under the high-dimensional situation where the number of covariates exceeds the sample size,
and is potentially growing with the sample size. Our framework will be quite general in the sense that the
ideas presented will be applicable to a wide variety of causal estimands. For clarity, we will first focus on
binary treatments and the average treatment effect (ATE), which is defined as ∆ = E(Y (1)− Y (0)). Here,
Y (t) is the potential outcome that would have been observed under treatment T = t.
For binary treatments, identification of the average treatment effect based on the observed data relies on
the stable unit treatment value assumption (SUTVA) (Little & Rubin, 2000), unconfoundedness, and posi-
tivity. SUTVA implies that the treatment received by one observation or unit does not affect the outcomes
of other units and the potential outcomes are well-defined in the sense that there are not different versions
of the treatment that lead to different potential outcomes. Unconfoundedness and positivity can be defined as:
Unconfoundedness: Y (t) ⊥ T |X for t=0,1
Positivity: There exist δ ∈ (0, 1) such that 0 < δ < P (T = 1|X) < 1− δ < 1.
where P (T = 1|X) denotes the propensity score (Rosenbaum & Rubin, 1983). There exists analagous
assumptions when estimating the effect of a continuous treatment on an outcome, though we refer readers
to previous literature on the topic for more details (Gill & Robins, 2001; Hirano & Imbens, 2004; Kennedy
et al. , 2017).
2.1 Modeling framework
Throughout the manuscript we will posit a model for both the treatment and outcome as many estimators
of the ATE can be defined as a function of one or the both of them. While we will always be utilizing
both models, if an estimator relies on only one of the two models, such as the inverse probability weighted
estimator, then the other model can be dropped from estimation as it would not impact the results. This is
due to the fact that the likelihood can be factorized via P (Y, T |X) = P (Y |T,X)P (T |X). We introduce:
h−1y (E(Yi|Ti,Xi)) = β0 + ft(Ti) +
p∑
j=1
fj(Xji) (1)
h−1t (E(Ti|Xi)) = α0 +
p∑
j=1
gj(Xji). (2)
Here, hy() and ht() are suitable link functions. For now the functional form of the relationships between
the covariates and the treatment or outcome is unspecified, and we will detail how we estimate them in the
following sections. These models assume that the effects of the covariates on the treatment and outcome are
additive, which is an assumption we make to reduce the complexity of estimation in high-dimensions. We
use this formulation, because many well-known estimators can be obtained from the fitted values of these
two models. For instance, a doubly robust estimator of the ATE can be constructed as
∆˜ =
1
n
[
n∑
i=1
TiYi
p∗1i
− Ti − p
∗
1i
p∗1i
m∗1i
]
− 1
n
[
n∑
i=1
(1− Ti)Yi
p∗0i
+
Ti − p∗1i
p∗0i
m∗0i
]
, (3)
where p∗ti = P (Ti = t|Xi), and m∗ti = E(Yi|Ti = t,Xi) represent the true values of the treatment and
outcome models, respectively. If we have posterior samples of the parameters for the outcome and treatment
models then we automatically have posterior samples of the doubly robust estimator as well, where we plug
in the posterior samples in place of the true values. One might expect that by having posterior samples of
the above estimator, we can automatically create credible intervals and perform inference on ∆. This is not
the case, however, since the posterior distribution conditions on Y and T treating them as fixed quantities.
In the estimator of equation 3, Y and T are random quantities and their uncertainty must be accounted for.
In Cefalu et al. (2016), the authors built a doubly robust estimator based on Bayesian model averaging, and
performed inference with the bootstrap, which requires re-fitting the models for each bootstrap sample. We
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will see in Section 4 that a small resampling procedure can account for all sources of uncertainty with only
one MCMC run, greatly reducing computation time.
Further, since we are in a high-dimensional setting and therefore some form of variable selection or
dimension reduction is necessary, we will imbed spike and slab priors (George & McCulloch, 1993) into these
models to reduce the parameter space and allow for more efficient estimation when the number of covariates is
large. In the following sections we will highlight two different flexible approaches to estimating the unknown
functions, and how to utilize variable selection within each formulation.
2.2 Guassian process prior specification
Here we adopt fully nonparametric priors for the unknown regression functions, fj() and gj() for j = 1, . . . , p.
We present the prior specification for the outcome model only, but analogous representations are used for
the treatment model. We use a Gaussian process prior with kernel function K(·, ·), which means we can
represent our prior as follows:
fj(Xj) ∼ (1− γj)δ0 + γjN (0n, σ2τ2j Σj) (4)
γj ∼ Bernoulli(θ) θ ∼ B(aθ, bθ) (5)
τ2j ∼ Gamma(1/2, 1/2) σ2 ∼ InvGamma(aσ2 , bσ2). (6)
Here, σ2 is the residual variance of the model when the outcome is normally distributed, otherwise it is
simply fixed to 1. Our prior formulation resembles that of Reich et al. (2009), who performed variable
selection within Gaussian processes. We utilize a latent variable, γj , which indicates whether variable j is
important for predicting the outcome. If γj = 0 then the predictor is eliminated from the model completely.
We will assume the prior on the variance τ2j to be a gamma(1/2, 1/2) similarly to Mitra & Dunson (2010).
Finally, Σj is a covariance matrix with the (i, i
′) component being K(Xji, Xji′). Throughout we will proceed
with K(z, z′) = exp− |z−z′|φ , where φ is a bandwidth parameter that must be chosen.
The formulation above is nonparametric in the sense that we assume no parametric form about the
response functions fj(Xj). This removes the burden from the user of having to pre-specify any functional
forms between the covariates and the outcome. One criticism of using Gaussian processes is that they can
be very computationally burdensome, particularly as the sample size increases, because at each iteration of
an MCMC one must invert an n by n matrix. Reich et al. (2009) showed that this can be avoided by using
a singular value decomposition on the kernel covariance matrices before running the MCMC. Details of this
can be found in their paper or in Appendix B. This allows us to utilize Gaussian processes in reasonably
sized data sets, but the computation can still be slow for large sample sizes.
2.3 Semiparametric prior specification
In this section, we present an analogous formulation of the problem, where we drop the fully nonparametric
Gaussian process and replace it with a semi-parametric model based on basis functions, such as cubic splines.
This reduces the amount of flexibility in estimation of fj(Xj) as we are restricting the class of functions
permitted by our prior specification, but greatly reduces the computational complexity and allows us to
model much larger data sets. To do this, we must introduce some additional notation. We let X˜j represent
an n by q matrix of basis functions used to approximate the relationship between Xj and the outcome. In
the case of cubic splines this would represent modeling fj(Xj) with q-degrees of freedom splines. We can
now write our prior specification as follows:
fj(Xj) = X˜jβj (βj |γj) ∼ (1− γj)δ0 + γjψ(βj) (7)
γj ∼ Bernoulli(θ) θ ∼ Beta(aθ, bθ) σ2 ∼ InvGamma(aσ2 , bσ2). (8)
Here we have placed a multivariate spike and slab prior on the group of coefficients, βj , that will force all
coefficients to zero and eliminate covariate j from the model if γj = 0. If γj = 1, then all elements of βj
will be nonzero and their prior distribution will be ψ(βj), which we will set to be a multivariate normal
distribution centered at 0 with covariance set to σ2σ2βIn. We must select a value of σ
2
β, which can be done
either via empirical Bayes or by placing a hyper prior on σ2β.
2.4 Estimation of treatment effects
In the previous sections we detailed how to build the treatment and outcome models required in high-
dimensions, so now we will illustrate how to use the model estimates to acquire estimates of treatment effects
while propagating uncertainty. To do so, we will highlight how the doubly robust estimator in Equation 3
could be implemented within our modeling strategy. Letting b = 1, . . . , B represent the B iterations of an
MCMC, once we have samples of the treatment and outcome model parameters, fj(Xj)
(b) and gj(Xj)
(b),
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then we automatically obtain samples of P (Ti = t|Xi) and E(Yi|Ti = t,Xi), denoted by p(b)ti and m(b)ti ,
respectively. Given these quantities, we can estimate the posterior mean of the doubly robust estimator via
∆̂ =
1
Bn
B∑
b=1
[
n∑
i=1
TiYi
p
(b)
1i
− Ti − p
(b)
1i
p
(b)
1i
m
(b)
1i
]
−
[
n∑
i=1
(1− Ti)Yi
p
(b)
0i
+
Ti − p(b)1i
p
(b)
0i
m
(b)
0i
]
. (9)
Typically, by having a posterior distribution of a given quantity, we can also conduct inference since we can
use the quantiles or standard deviation of the posterior samples to construct credible intervals. However, this
is not the case here. In an extreme scenario where the true values of p∗ti and m
∗
ti are known, there will be no
uncertainty in the posterior distribution of ∆. This arises from the fact that posterior distributions condition
on the observed data and do not take into consideration uncertainty stemming from Y and T . In Section 4 we
will detail how to supplement the MCMC samples with a computationally efficient bootstrapping procedure
to estimate the standard error of our estimator with only one MCMC run.
3 Contraction rate of the treatment effect
Convergence rates of treatment effects are typically established in the frequentist literature, particularly in
high-dimensional models when achieving
√
n−consistency is not trivial. We will restrict attention to the
doubly robust setting, which is particularly of interest in high-dimensional scenarios because it allows us to
achieve better rates of contraction than approaches based on a single model. In the semi-parametric causal
inference literature this has been used to allow for machine learning approaches that converge at n1/4 rates or
high-dimensional models that converge at
√
n/ log p rates (Chernozhukov et al. , 2016; Farrell, 2015). Here,
we establish that these same ideas carry over into posterior contraction rates for the posterior distribution
of the treatment effect. It might appear counterintuitive to prove posterior contraction rates when we have
previously stated that our approach is not fully Bayesian. We do in fact have a fully Bayesian posterior of the
quantity in equation 3 if we treat Y and T as fixed quantities. We will show that the posterior distribution
of this quantity, when averaged over the distribution of Y and T , contracts at a particular rate. Throughout
the rest of this section when we refer to a posterior distribution, it is this that we are referring to. This
quantity is important to look at, as it establishes convergence rates of specific features of the distribution,
such as the posterior mean, which we are using as our estimate of the causal effect.
3.1 Notation and assumptions
Let pti = P (Ti = t|Xi), mti = E(Y (t)|Xi), and E(Y (t)) = µt, where each of these can be estimated us-
ing the parameters in our model specification above. We will denote their true values as p∗ti, m
∗
ti, and µ
∗
t ,
respectively. Let D represent the observed data. Throughout this section, we will utilize the subscripts n
and P0 to represent moments with respect to the posterior distribution and true data generating process,
respectively. In particular Pn represents the posterior distribution given a sample of n observations, and EP0
is the expected value with respect to P0, the true data generating process. Before we detail our result on
posterior contraction, we must highlight a few assumptions.
Assumption 1 (Data generating process).
(a) {(Yi, Ti,Xi)}ni=1 are i.i.d samples from P0
(b) The covariates Xj have bounded support, in that there exists Kx < ∞ such that |Xj | < Kx with
probability 1 for all j.
(c) sup
P0
EP0((Y −m∗ti)2) ≤ Ky <∞.
Assumption 1a restricts analysis to the cross-sectional setting. Assumption 1b is likely to be satisfied in
real applications as nearly all underlying variables are naturally bounded. Assumption 1c ensures that the
residual variance of the outcome is bounded, which again should be satisfied in most applications. Next, we
place bounds on the posterior distribution of our treatment and outcome model:
Assumption 2 (Bounds on the error of posterior distributions).
(a) sup
P0
EP0Varn
(
pti−p∗ti
pti
|Di
)
≤ Kp <∞
(b) sup
P0
EP0Varn
(
mti −m∗ti|Di
)
≤ Km <∞
Assumption 2a effectively states that the posterior distribution of pti does not assign mass to neighborhoods
of 0, and can be satisfied through prior distribution constraints. Assumption 2b states that the difference
between the true conditional mean of the outcome and the corresponding posterior is bounded. If Y is
categorical this is automatically satisfied, and is a very mild assumption even if Y is continuous. Finally, we
detail the assumptions required on either the treatment or outcome model:
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Assumption 3 (Posterior contraction of treatment and outcome models). Suppose there exist two sequence
of numbers nt → 0 and ny → 0, and constants Mt > 0 and My > 0 that are independent of nt and ny,
respectively, such that
(a) sup
P0
EP0Pn
(
1√
n
||pt − p∗t || > Mtnt|D
)
→ 0
and
(b) sup
P0
EP0Pn
(
1√
n
||mt −m∗t || > Myny|D
)
→ 0,
where ||v|| =
√
v21 + · · ·+ v2n. Assumption 3a and 3b state that the posterior distribution of the treatment
and outcome models contract at rates nt and ny, respectively. Achieving rates of posterior contraction
such as these typically relies on their own set of assumptions, such as conditions on the design matrix X or
sparsity. We will restrict discussion of these issues to relevant papers on posterior contraction in regression
models (Castillo et al. , 2015; Yang et al. , 2015; Yoo et al. , 2016). Our key goal is to show what happens
to the posterior of the treatment effect, conditional on the fact that either the posterior distribution of the
treatment or outcome model contracts at a given rate. In particular, we will show that we only need to rely
on assumption 3a or 3b to achieve posterior contraction of µt, though having both 3a and 3b satisfied will
improve the rate of posterior contraction. Further, we will show that this result holds uniformly over P0.
3.2 Posterior contraction
Now we are in a position to state the posterior contraction result for µt. While we restrict attention to µt
for simplicity, the extension to µ1 − µ2 is trivial. We seek to find a minimum possible sequence of numbers
n → 0, and a constant M , which does not depend on n, such that
sup
P0
EP0Pn(pt,mt : |µt − µ∗t | > Mn|D)→ 0, (10)
where n defines the rate of contraction of the posterior. The faster that n converges to zero while main-
taining this result implies that our posterior distribution contracts at a faster rate.
Theorem 1: Assume positivity, no unmeasured confounding, SUTVA, assumption 1, and assumption 2. If
assumption 3a and 3b hold, Equation 10 is satisfied with n = max(n
−1/2, ntny). If only one of assumptions
3a or 3b hold, Equation 10 is satisfied with n = max(n
−1/2, ηn), where ηn is the contraction rate for the
correctly specified model.
A proof of this result can be found in Appendix A. In high-dimensions where regression parameters will
contract at slower rates than n−1/2, we can still obtain a contraction rate of the treatment effect that is
n−1/2 if the product of their contraction rates is less than or equal to n−1/2. For instance, it is well under-
stood that in high-dimensional linear regression, the posterior contraction rate of regression coefficients when
using spike and slab priors is
√
log p/n (Castillo et al. , 2015). If both the treatment model and outcome
model parameters contract at this rate, then the posterior distribution of the treatment effect still contracts
at n−1/2 as long as log p ≤ n3/2. Our result has implications for low-dimensional models as well. If one is
interested in using nonparametric priors, which contract more slowly than parametric models, but allow for
highly flexible modeling of the regression models, n−1/2 contraction can still be obtained under the same
logic. Of course, one of the main implications of this theorem, regardless of the covariate dimension, is that
posterior consistency is achieved as long as only one model is correctly specified (double robustness).
4 Resampling for improved inference
As discussed in Section 2.4, directly plugging in posterior samples of the treatment and outcome model into
the doubly robust estimator does not account for all the sources of uncertainty because they ignore the
additional uncertainty from the data. To see how we can alleviate this issue we can write out the variance
decomposition formula in our context where Ψ represents all parameters in our model:
Var(∆̂) = EY,T (VarΨ(∆̂|Y, T )) + VarY,T (EΨ(∆̂|Y, T )) (11)
Now we have explicitly accounted for the variation in (Y, T ), whereas if we simply looked at the posterior
distribution of ∆ we would obtain VarΨ(∆̂|Y, T ) and would underestimate the variance. All expectations
and variances with respect to Ψ can be calculated from the posterior samples, but now we will introduce a
bootstrapping procedure to estimate the moments that are with respect to (Y, T ).
We will adopt the standard nonparametric bootstrap (Efron & Tibshirani, 1994), which involves drawing
n samples with replacement from our data. We will do this M times to create M resampled data sets.
For each of the resampled data sets, we can calculate the estimator of interest for each of the b = 1, . . . , B
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posterior draws of the unknown parameters. This leaves us with MB estimates of the quantity of interest,
which is depicted by the matrix below. In the matrix, the rows correspond to the estimates for a given data
set, while the columns represent estimates from a given MCMC draw.
∆̂11 ∆̂12 . . . ∆̂1B
∆̂21
. . . ∆̂2B
...
. . .
...
∆̂M1 ∆̂M2 . . . ∆̂MB

To calculate EY,T (VarΨ(∆̂|Y, T )) we could calculate the variance of the estimates within each row, which
will leave us with an M−dimensional vector of conditional variances. Then we can simply average across
the M conditional variances to get their expectation with respect to (Y, T ). An analagous operation could
be performed to estimate VarY,T (EΨ(∆̂|Y, T )), and combining these quantities according to (11) gives us an
estimate of Var(∆̂). This can be used in conjuction with a normal approximation to construct confidence
intervals for ∆. This reduces the computation burden dramatically, requiring the calculation of the estimator
MB times, which is much faster than even one additional MCMC run, let alone M .
Inference should propagate uncertainty arising from two sources: 1) uncertainty in parameter estimation,
and 2) the inherent data variability. It might seem counterintuitive to use the bootstrap here, which has been
shown to fail in other contexts with variable selection (Chatterjee & Lahiri, 2010). However, a key distinction
is that we are not using the bootstrap to account for uncertainty in parameter estimation. Instead, parameter
uncertainty is accounted for through the parameters posterior distribution. Then, conditional on parameter
values from the posterior, the bootstrap is employed to account for the inherent data variability. Note
that the bootstrap provides valid inference conditional on known parameter values, since the doubly robust
estimator is simply a sum of i.i.d random variables depending on Yi and Ti.
5 Simulation studies
Here we present results on simulated data to assess the performance of our proposed approach in a number
of settings.
5.1 Binary treatments
Here, we will restrict attention to n = 100 and p = 500, and we will generate data from the following setup:
Yi|Ti,Xi ∼ N (µi, In)
Ti|Xi ∼ Bernoulli(pi)
Xi ∼ N(0p,Σ).
Throughout, we will assume that Σij = 1 if i = j and Σij = 0.3 if i 6= j. We will simulate data under two
scenarios for the true propensity and outcome regressions:
Linear Simulation: µi = Ti + 0.75X1i +X2i + 0.6X3i − 0.8X4i − 0.7X5i
pi = Φ(0.15X1i + 0.2X2i − 0.4X5i)
Nonlinear Simulation: µi = Ti + 0.8X1i + 0.4X
3
2i + 0.25e
|X2i| + 0.8X25i − 1.5sin(X5i)
pi = Φ(0.15X1i − 0.4X2i − 0.5X5i)
We will be estimating the average treatment effect using: a) double post selection regression (Double PS)
introduced in Belloni et al. (2014); b) doubly robust estimators (lasso-DR) introduced in Farrell (2015);
c) the residual de-biasing approach (De-biasing) of Athey et al. (2018); d) Targeted maximum likelihood
(TMLE, Van Der Laan & Rubin (2006)) with lasso models; and e) the double machine learning approach
(DML, Chernozhukov et al. (2016)) with lasso models. For each of these approaches, asymptotic standard
errors were estimated, and confidence intervals were defined as the interval within 1.96 estimated standard
errors of the point estimate. For the nonlinear scenarios we will only compare with TMLE and double
machine learning, as the other approaches rely on linearity of models and do not immediately extend to
nonlinear scenarios. For both of these approaches, we use an initial screening step from a group lasso model,
and then fit nonlinear outcome models on the chosen covariates. Treatment models are still built with linear
models as the true treatment model is linear. More details of our implementation of these approaches can
be found in Appendix C. Using the Bayesian methods described above we will estimate the treatment effect
using doubly robust estimators. For the treatment and outcome models, we will consider linear models,
models using 3 degree of freedom splines for each covariate, and models that use Gaussian process priors for
each covariate. We will show the results for the doubly robust estimator that uses the best treatment and
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outcome model as chosen by WAIC (Watanabe, 2010), which is a Bayesian analog of commonly used model
selection criteria such as AIC or BIC. We will refer to this doubly robust estimator as Bayes-DR.
Figure 1 shows the results from the two simulation studies across both scenarios examined. The estimator
proposed in this paper is in grey, while the existing approaches can be found in black. In the linear scenario,
the models that estimate treatment effects using linear outcome models do very well, as the Double PS,
TMLE, and DML approaches do very well. Importantly, the Bayes-DR estimator is the only estimator that
achieves interval coverages near the nominal level. In the nonlinear simulation, we see that our estimator
obtains the lowest MSE of all approaches, and again achieves coverages close to the nominal level.
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Figure 1: Results from simulations with binary treatments. The top panel shows
results for the linear scenario, while the bottom panel shows results for the nonlinear
scenario. The first column shows mean squared error, while the second column shows
95% interval coverages.
5.2 Continuous treatments
Here, we will restrict attention to n = 200 and p = 200, and we will generate data from the following setup:
Yi|Ti,Xi ∼ N (µyi , In) (12)
Ti|Xi ∼ N (µti, In) (13)
Xi ∼ N(0p,Σ), (14)
where
µyi = 5 + 0.05T
3
i − 0.1T 2i + 0.6X1i + 0.4exp(X1i) + log(abs(0.65X2i)) + 0.5(1 +X3i)2
µti = 0.6X
2
1i + 0.6X1i + exp(abs(0.65X2i))− 0.8X23i,
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and Σij = 1 if i = j and Σij = 0.3 if i 6= j. Our estimand of interest is now the entire exposure response
curve, therefore we will be estimating E(Y (t)) for all t in the support of T . To estimate this quantity for
all t we will use our models as described above and then apply either regression based estimators that only
utilize the outcome model and marginalize over the covariate distribution, or the doubly robust estimator
that was introduced in Kennedy et al. (2017). We will refer to the regression based estimators as Reg-1,
Reg-3, and Reg-GP to denote the amount of nonlinearity allowed. The doubly robust estimator involves
creating a pseudo-outcome:
ξ(Di,Ψ) =
Yi − E(Yi|Ti,Xi)
p(Ti = t|Xi)
∫
X
p(Ti = t|Xi)dPn(X) +
∫
X
E(Yi|Ti,Xi)dPn(X), (15)
where Pn is the empirical distribution of the data. Then, this pseudo-outcome is regressed against the
treatment, potentially in a flexible manner so that the exposure-response curve can be nonlinear. We will
use this estimator, where the treatment and outcome models are built using the Bayesian machinery above
to reduce the dimension of the covariate space, and then perform inference using the resampling approach
described in Section 4. Both the treatment and outcome models assume normality of the outcome. To assess
the performance of the various methods at estimating the whole curve, we will evaluate the performance
of each method at 20 distinct locations on the curve and average relevant metrics such as bias or interval
coverage across the 20 locations. We will use cubic polynomials to model the exposure-response curve, which
encaptures the true curve, though any flexible approach could work here.
Figure 2 shows the results averaged across 1000 simulations. The Reg-1 estimator does very poorly in
terms of MSE and interval coverages, which is expected because it assumes linearity, when the true model
is highly nonlinear. The Reg-3, Reg-GP, and Bayes-DR approaches all allow for nonlinear relationships
between the covariates and treatment/outcome, and therefore these approaches perform well with respect
to the metrics looked at. Again, our Bayes-DR estimator achieves interval coverages at or near the nominal
level of 95%. The right panel of Figure 2 shows that the Bayes-DR estimator generally estimates the entire
curve well, with very few simulations deviating from the true shape.
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Figure 2: Simulation results for continuous treatments. The left panel presents the
mean squared error, the middle panel shows the 95% credible interval coverage, and
the right panel shows the estimates of the exposure-response curve across the 1000
simulations for the doubly robust estimator.
5.3 Summary of additional simulation results
In Appendices D-F we present additional simulation results using different data generating mechanisms,
different p/n ratios, and bootstrap inference for the competing approaches. We find similar results under
different data generating mechanisms that show our approach to inference does better in terms of finite
sample interval coverage, and does well in terms of MSE. As we increase the sample size and p/n ratio, this
difference disappears as the asymptotic standard errors of existing approaches perform much better and more
closely match our results. The bootstrap is not theoretically justified for every competing approach, though
we applied it to assess if our approach to inference was only doing better because it was the only approach
using resampling. We found the bootstrap intervals to be excessively large due to the erratic nature of the
estimators in small samples, leading to interval coverages of 100% and very little power to detect signals.
As the sample size increased, this problem also disappears and the bootstrap intervals perform very well,
though only in scenarios when the asymptotic intervals also perform well.
6 Application to EWAS
Environmental wide association studies (EWAS) have been increasingly common in recent years as scientists
attempt to gain a better understanding of how various chemicals and toxins affect the biological processes
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in the human body (Wild, 2005; Patel & Ioannidis, 2014). In particular, EWAS look to study the effects
of a large number of exposures that humans are invariably exposed to on disease or other functions in the
body. The National Health and Nutrition Examination Survey (NHANES), is a cross-sectional data source
made publicly available by the Centers for Disease Control and Prevention (CDC). We will restrict attention
to the 1999-2000, 2001-2002, 2003-2004, and 2005-2006 surveys, and we will aim to estimate the effects of
environmental exposures on three different outcomes: HDL cholesterol levels, LDL cholesterol levels, and
triglyceride levels in humans. We will use the data found in Wilson et al. (2018), which studied the impact of
environmental agents from the NHANES data. The study contains a large number of potential confounders
as participants fill out questionnaires regarding their health status, and receive clinical and laboratory tests
that contain information on environmental factors such as pollutants, allergens, bacterial/viral organisms,
chemical toxicants, and nutrients. In previous work (Patel et al. , 2012), the environmental agents for which
we want to estimate the causal effects of, were separated into different groups containing similar agents that
might affect similar biological pathways. We will look at the effects of 14 different environmental agent
groups on the three outcomes, leading to 42 different analyses. Each exposure we look at is defined as the
average exposure level across all agents within the same grouping. In the NHANES data, different subjects
had different environmental agents measured, leading to different populations, covariate dimensions, and
sample sizes for each of the 14 different exposures. We apply our Bayesian models in conjuction with the
doubly robust estimator of Kennedy et al. (2017) to estimate the exposure response curves for each of the
42 analyses. Both p and n vary for each data set, however, there is a wide range of p/n ratios from 0.08 to
0.51, with a mean of 0.25.
6.1 Differing levels of nonlinearity and sparsity
To analyze the data we fit a treatment model and an outcome model under each of the three levels of
flexibility that we used in the simulation study. This includes a linear function of the covariates, three degree
of freedom splines, and Gaussian processes. For each data set we looked at the WAIC of both the treatment
and outcome model, and used the model with the minimum WAIC for the doubly robust estimate of the
exposure response curve. Figure 3 shows histograms of the ratio of the WAIC values with the minimum
WAIC within a given dataset across the three models. A value of one indicates that a particular model had
the best WAIC, while larger values indicate worse fits to the data. We see that for the treatment model, the
Gaussian process prior does the best as it is selected more than any other model and most of the values in
the histogram are less than 1.05. Linear models do the next best and have the lowest WAIC for a number
of datasets, while the spline model does the worst overall. For the outcome model, the linear model does
best, followed by the Gaussian process prior and spline model, which do similarly well. Overall, these plots
suggest that differing amounts of flexibility were required in these analyses, and our flexible approach might
be more accurately depicting the true data generating processes.
Now we can also examine the extent to which our sparsity inducing priors reduced the dimension of
the covariate space. While our models provide posterior inclusion probabilities, we can report a binary
assessment of a variable’s importance by reporting whether the posterior inclusion probability is greater
than 0.5. Figure 3 shows the percentage of covariates that have a posterior inclusion probability greater than
0.5 in the treatment and outcome models. It is clear from both the treatment and outcome models that the
spike and slab priors are greatly reducing the number of covariates in the model as all datasets have less
than 30% of the covariates in the models, and many are less than 10%. Not shown in the figure is that there
are even fewer covariates included in both models, indicating that there is not a lot of strong confounding
within these datasets. This is further supported by the fact that many of the estimated exposure response
curves are very similar to the curves one would get by not controlling for any covariates.
6.2 Exposure response curves
Here, we will highlight the estimation of the exposure response curves for three of the exposures in the
analysis: Dioxins, Organochlorine pesticides, and Diakyl. The p/n ratio for these three analyses was 0.41,
0.18, and 0.34, respectively. Figure 4 shows the doubly robust estimate of the exposure response curve along
with the naive curve one would get by not including any covariates in the analysis. The two estimated
curves are fairly similar with a couple of exceptions. The effect of OC pesticides on Triglycerides has a
much smaller slope when adjusting for covariates, and the effect of Diakyl on Triglycerides is much larger at
lower levels of exposure when adjusting for covariates. In some areas of the curves there is less uncertainty
in the doubly robust estimate, however, in general the naive curves are somewhat more efficient. This is
not entirely surprising as the doubly robust estimators are adjusting for a large number of covariates, which
can decrease efficiency unless the covariates are highly predictive of the outcome. Importantly, however, the
confidence intervals of the doubly robust estimator are not much wider than the naive curves, indicating that
the dimension reduction from the spike and slab priors is helping with efficiency.
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Figure 3: The top panel presents the ratio of WAIC values to the minimum values for
each of the three models considered. The top left panel shows the treatment model
WAIC values, while the top right panel shows the WAIC for the outcome models. The
bottom panel shows the percentage of covariates included in the chosen treatment and
outcome model.
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Figure 4: Estimated exposure response curves from the doubly robust estimator (black
line) as well as the naive curve (red line), which does not adjust for any covariates.
7 Discussion
We have introduced a Bayesian approach for causal inference that has a number of desirable features. Our
approach can be applied to semiparametric estimators of causal effects that rely on a treatment or outcome
model, in the context of binary, categorical, or continuous treatments. This is particularly important as
the literature on estimating the causal effect curve for continuous treatments is small, and has not been
extended to high-dimensional scenarios. We showed our approach maintains asymptotic properties such as
double robustness and posterior contraction rates, while showing improved performance in finite samples.
In particular, our approach to inference is able to capture all of the uncertainty in the data, leading to
nominal interval coverages when frequentist counterparts that rely on asymptotics have decreased interval
coverage. Further, flexible Bayesian methods allow our approach to adapt to nonlinear relationships in the
treatment and outcome models, reducing the impact of model misspecification. Our approach has widespread
applicability, as many causal estimators can be written as functions of treatment and outcome models, and
the ideas seen here will apply directly. This allows users to estimate causal effects using many desirable
Bayesian tools such as nonparametric priors and spike and slab priors, to name a few. While we focused
on high-dimensional scenarios with spike and slab priors in this paper, the ideas presented apply to any
type of modeling framework for the treatment and outcome models. Throughout, we have assumed that the
treatment effect is homogeneous, i.e. that the treatment effect is constant across all levels of the covariate
space. This assumption can easily be removed when the treatment is categorical by building separate outcome
models for each level of the treatment, again using the flexible Bayesian models described in the manuscript.
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Doubly robust estimation was first introduced in the Bayesian framework in Saarela et al. (2016),
although there has been some debate about whether an estimate of counterfactual outcomes can utilize the
propensity score within the Bayesian framework (Saarela et al. , 2015). Robins & Ritov (1997) showed
that any Bayesian analysis honoring the likelihood principle can not utilize the propensity score. We take
a somewhat different approach in this paper, as we do not attempt to address these concerns, nor are we
concerned with whether or not the proposed approach is “fully” Bayesian. Our purpose is to show that
Bayesian methods can be coupled with estimating equation based estimators in causal inference to provide
flexible alternatives with desirable finite sample properties, and that this is even more important in high-
dimensional scenarios where model uncertainty is higher and relying on asymptotics does not work well.
An important point is understanding why our approach to uncertainty estimation does better in finite
samples than existing approaches rooted in asymptotic theory. Asymptotic approaches rely on certain
terms vanishing as the sample size increases, though this doesn’t hold in finite samples, and ignoring these
additional terms can lead to anti-conservative inference. We do not make any such assumptions. We account
for uncertainty in parameter estimation through the posterior distributions of our treatment/outcome models,
while we account for any additional uncertainty in the causal estimate through resampling. As the sample
size increases, any differences in these two approaches to inference should dissipate.
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Appendix A: Proof of posterior contraction rates
Proof: For simplicity we will drop the pt,mt notation in Equation 10 and write the quantity of interest as
follows:
sup
P0
EP0Pn(|µt − µ∗t | > Mn|D) = sup
P0
EP0Pn
(
1
n
∣∣∣∣∣
n∑
i=1
1(Ti = t)
pti
(Yi −mti) +mti − µ∗t
∣∣∣∣∣ > Mn|D
)
= sup
P0
EP0Pn
(
1
n
∣∣∣∣∣
n∑
i=1
1(Ti = t)
pti
(Yi −mti) +mti
− 1(Ti = t)
p∗ti
(Yi −m∗ti)−m∗ti
+
1(Ti = t)
p∗ti
(Yi −m∗ti) +m∗ti − µ∗t
∣∣∣∣∣ > Mn|D
)
= sup
P0
EP0Pn
(∣∣∣∣∣A+B
∣∣∣∣∣ > Mn|D
)
.
where we can define A and B as follows:
A =
1
n
n∑
i=1
1(Ti = t)
pti
(Yi −mti) +mti − 1(Ti = t)
p∗ti
(Yi −m∗ti)−m∗ti
B =
1
n
n∑
i=1
1(Ti = t)
p∗ti
(Yi −m∗ti) +m∗ti − µ∗t
After re-arranging some terms, we can further decompose A into three separate parts such that A = A1 +
A2 +A3 where each are defined below:
A1 =
1
n
n∑
i=1
(mti −m∗ti)
(
1− 1(Ti = t)
p∗ti
)
A2 =
1
n
n∑
i=1
1(Ti = t)(pti − p∗ti)(m∗ti − Yi)
ptip∗ti
A3 =
1
n
n∑
i=1
1(Ti = t)(pti − p∗ti)(mti −m∗ti)
ptip∗ti
.
We can now write the probability as
sup
P0
EP0Pn(|µt − µ∗t | > Mn|D) = sup
P0
EP0Pn(|A1 +A2 +A3 +B| > Mn|D)
≤ sup
P0
EP0Pn(|A1| >
M
4
n|D) + sup
P0
EP0Pn(|A2| >
M
4
n|D)
+ sup
P0
EP0Pn(|A3| >
M
4
n|D) + sup
P0
EP0Pn(|B| >
M
4
n|D),
so it now suffices to show that each of the four components above contracts at the n rate. We will begin with
the B component, which does not depend on either the posterior distribution of the treatment or outcome
model as it is simply the doubly robust estimator of µ1 evaluated at the true values for the propensity score
and outcome regression minus the parameter of interest.
sup
P0
EP0Pn(|B| >
M
4
n|D) = sup
P0
EP0Pn
(∣∣∣∣∣ 1n
n∑
i=1
1(Ti = t)
p∗ti
(Yi −m∗ti) +m∗ti − µ∗t
∣∣∣∣∣ > M4 n|D
)
= sup
P0
EP01
(∣∣∣∣∣ 1n
n∑
i=1
1(Ti = t)
p∗ti
(Yi −m∗ti) +m∗ti − µ∗t
∣∣∣∣∣ > M4 n
)
= sup
P0
PP0
(∣∣∣∣∣ 1n
n∑
i=1
1(Ti = t)
p∗ti
(Yi −m∗ti) +m∗ti − µ∗t
∣∣∣∣∣ > M4 n
)
.
The second equality holds because all of the components of B are components of D and are therefore just
constants when conditioning on D. The quantity inside of the absolute values is easily shown to have
expectation 0 with respect to P0 and therefore we can apply Chebyshev’s inequality to say:
sup
P0
EP0Pn(|B| >
M
4
n|D) ≤ sup
P0
16VarP0(B)
M22n
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= sup
P0
16σ2B
M22nn
where σ2B = VarP0
(
1(Ti=t)
p∗ti
(Yi −m∗ti)
)
≤ KB < ∞, for some constant KB by assumption 1 and positivity.
Clearly if n > n
−1/2 then this probability goes to zero and we have the desired result. Now, turning attention
to A1 let us first find En(A1|D), the posterior mean of A1.
En(A1|D) = En
(
1
n
n∑
i=1
(mti −m∗ti)
(
1− 1(Ti = t)
p∗ti
)
|D
)
=
1
n
n∑
i=1
(
1− 1(Ti = t)
p∗ti
)
En
(
(mti −m∗ti|D
)
.
This quantity is nonzero and therefore we can not directly apply Chebyshev’s inequality. We will add and
subtract the posterior mean as follows:
sup
P0
EP0Pn(|A1| >
M
4
n|D) = sup
P0
EP0Pn(|A1 − E(A1|D) + E(A1|D)| >
M
4
n|D)
≤ sup
P0
EP0Pn(|A1 − E(A1|D)| >
M
8
n|D)
+ sup
P0
EP0Pn(|E(A1|D)| >
M
8
n|D)
Our goal is now to show that both of these quantities tend to 0 as n→∞. We can use Chebyshev’s inequality
on the first of the two probabilities to see that
sup
P0
EP0Pn(|A1 − E(A1|D)| >
M
8
n|D) ≤ sup
P0
EP0
64Varn(A1|D)
M22n
= sup
P0
EP0
64σ2A11
M22nn
where EP0(σ
2
A11
) = EP0Varn
(
(mti − m∗ti)
(
1 − 1(Ti=t)p∗ti
)
|D
)
≤ KA11 < ∞, for some constant KA11 by
assumption 2 and positivity. Clearly, this limit goes to zero as long as n > n
−1/2. Now we can turn our
attention to the second probability below:
sup
P0
EP0Pn(|E(A1|D)| >
M
8
n|D).
Notice, however, that E(A1|D) is constant with respect to the posterior distribution of the parameters given
D, and therefore this quantity simplifies to
sup
P0
PP0(|E(A1|D)| >
M
8
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n
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8
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)
.
We will again use Chebyshev’s inequality to bound this quantity, but first we need to show that the quantity
inside the absolute value has expectation 0 with respect to P0.
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Where the fourth equality held due to the unconfoundedness assumption. Now we can apply Chebyshev’s
inequality to see that
sup
P0
PP0
(∣∣∣ 1
n
n∑
i=1
(
1− 1(Ti = t)
p∗ti
)
En
(
(mti −m∗ti|D
)∣∣∣ > M
8
n
)
≤ sup
P0
64σ2A12
M22nn
,
where σ2A12 = VarP0
((
1− 1(Ti=t)p∗ti
)
En
(
(mti−m∗ti)|D
))
≤ KA12 <∞ for some constant KA12 by assumption
2 and positivity. This expression goes to zero as long as n > n
−1/2. Now we can look at A2, which has a
similar construction as A1. Again, let us first calculate the posterior mean of A2.
En(A2|D) = En
(
1
n
n∑
i=1
1(Ti = t)(pti − p∗ti)(m∗ti − Yi)
ptip∗ti
)
|D
)
=
1
n
n∑
i=1
(
1(Ti = t)(m
∗
ti − Yi)
p∗ti
)
En
(
pti − p∗ti
pti
|D
)
.
Again, this quantity does not necessarily have mean 0 and therefore we can not directly apply Chebyshev’s
inequality, but we can add and subtract the mean as before.
sup
P0
EP0Pn(|A2| >
M
4
n|D) = sup
P0
EP0Pn(|A2 − E(A2|D) + E(A2|D)| >
M
4
n|D)
≤ sup
P0
EP0Pn(|A2 − E(A2|D)| >
M
8
n|D)
+ sup
P0
EP0Pn(|E(A2|D)| >
M
8
n|D).
Our goal is to show that both probabilities tend to zero and we have the desired result. For the first expression
we can apply Chebyshev’s inequality, since the quantity has mean 0:
sup
P0
EP0Pn(|A2 − E(A2|D)| >
M
8
n|D) ≤ sup
P0
EP0
64Varn(A2|D)
M22n
= sup
P0
EP0
64σ2A21
M22nn
where EP0(σ
2
A21
) = EP0Varn
(
1(Ti=t)(pti−p∗ti)(m∗ti−Yi)
ptip∗ti
|D
)
≤ KA21 < ∞ for some constant KA21 by assump-
tions 1, 2, and positivity. Clearly, this limit goes to zero as long as n > n
−1/2. Now we can turn our
attention to the second probability below:
sup
P0
EP0Pn(|E(A2|D)| >
M
8
n|D).
Notice, however, that E(A2|D) is constant with respect to the posterior distribution of the parameters given
D, and therefore this quantity simplifies to
sup
P0
PP0(|E(A2|D)| >
M
8
n) = sup
P0
PP0
(
1
n
n∑
i=1
(
1(Ti = t)(m
∗
ti − Yi)
p∗ti
)
En
(
pti − p∗ti
pti
|D
)
>
M
8
n
)
.
We will again use Chebyshev’s inequality to bound this quantity, but first we need to show that the quantity
inside the absolute value has expectation 0 with respect to P0.
EP0
(
1
n
n∑
i=1
(
1(Ti = t)(m
∗
ti − Yi)
p∗ti
)
En
(
pti − p∗ti
pti
|D
))
= EP0
((
1(Ti = t)(m
∗
ti − Yi)
p∗ti
)
En
(
pti − p∗ti
pti
|D
))
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= ET,X
[
EY |T,X
((
1(Ti = t)(m
∗
ti − Yi)
p∗ti
)
En
(
pti − p∗ti
pti
|D
))]
= ET,X
[(
1(Ti = t)
p∗ti
)
En
(
pti − p∗ti
pti
|D
)
EY |T,X(m∗ti − Yi)
]
= ET,X
[(
1(Ti = t)
p∗ti
)
En
(
pti − p∗ti
pti
|D
)
(m∗ti −m∗ti)
]
= 0
Now we can apply Chebyshev’s inequality to see that
sup
P0
PP0
(∣∣∣∣∣ 1n
n∑
i=1
(
1(Ti = t)(m
∗
ti − Yi)
p∗ti
)
En
(
pti − p∗ti
pti
|D
)∣∣∣∣∣ > M8 n
)
≤ sup
P0
64σ2A22
M22n
,
where σ2A22 = VarP0
((
1(Ti=t)(m
∗
ti−Yi)
p∗ti
)
En
(
pti−p∗ti
pti
|D
))
≤ KA22 < ∞ for some constant KA22 by as-
sumptions 1, 2, and positivity. This expression goes to zero as long as n > n
−1/2. Finally, we need to
show contraction rates for A3, which is where the double robustness property can be seen for the posterior
distribution of µt.
sup
P0
EP0Pn(|A3| >
M
4
n|D)
= sup
P0
EP0Pn
(∣∣∣∣∣ 1n
n∑
i=1
1(Ti = t)(pti − p∗ti)(mti −m∗ti)
ptip∗ti
∣∣∣∣∣ > M4 n|D
)
≤ sup
P0
EP0Pn
(√√√√ 1
n
n∑
i=1
(
1(Ti = t)(pti − p∗ti)
ptip∗ti
)2√√√√ 1
n
n∑
i=1
(mti −m∗ti)2 >
M
4
n|D
)
≤ sup
P0
EP0Pn
(√√√√ 1
n
n∑
i=1
KA31(pti − p∗ti)2
√√√√ 1
n
n∑
i=1
(mti −m∗ti)2 >
M
4
n|D
)
= sup
P0
EP0Pn
(
1
n
||pt − p∗t || ||mt −m∗t || >
Mn
4
√
KA31
|D
)
.
The first inequality comes from the Cauchy-Schwartz inequality, and the second inequality holds true for
some constant 0 < KA31 < ∞ from assumption 2. Using the law of total probability we can separate this
probability into scenarios when the outcome model contracts at rate ν1n , and when it doesn’t.
sup
P0
EP0Pn(|A3| >
M
4
n|D)
≤ sup
P0
EP0
[
Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31
1√
n
||mt −m∗t ||
|D, 1√
n
||mt −m∗t || < ν1n
)
× Pn
(
1√
n
||mt −m∗t || < ν1n |D
)
+ Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31
1√
n
||mt −m∗t ||
|D, 1√
n
||mt −m∗t || ≥ ν1n
)
× Pn
(
1√
n
||mt −m∗t || ≥ ν1n |D
)]
First, let’s assume that the outcome model contracts at the ν1n rate, i.e sup
P0
EP0Pn( 1√n ||mt−m∗t || < ν1n |D)→
1.
sup
P0
EP0Pn(|A3| >
M
4
n|D)
≤ sup
P0
EP0
[
Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31
1√
n
||mt −m∗t ||
|D, 1√
n
||mt −m∗t || < ν1n
)
× Pn
(
1√
n
||mt −m∗t || < ν1n |D
)]
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+ sup
P0
EP0
[
Pn
(
1√
n
||mt −m∗t || ≥ ν1n |D
)]
≤ sup
P0
EP0
[
Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31
1√
n
||mt −m∗t ||
|D, 1√
n
||mt −m∗t || < ν1n
)]
+ sup
P0
EP0
[
Pn
(
1√
n
||mt −m∗t || ≥ ν1n |D
)]
≤ sup
P0
EP0
[
Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31
ν1
n
|D
)]
+ sup
P0
EP0
[
Pn
(
1√
n
||mt −m∗t || ≥ ν1n |D
)]
= sup
P0
EP0
[
Pn
(
1√
n
||pt − p∗t || >
M1−ν1n
4
√
KA31
|D
)]
+ sup
P0
EP0
[
Pn
(
1√
n
||mt −m∗t || ≥ ν1n |D
)]
.
The first of these two expressions converges to 0 if the treatment model contracts at the 1−ν1n rate. The
second expression converges to 0 by the definition of posterior contraction for the outcome model. This
shows that if both the treatment and outcome model contract, then the posterior of the average treatment
effect contracts at a faster rate than either of the individual models. We saw earlier that A1, A2, and B
contract at the n = n
−1/2 rate and therefore the average treatment effect can not contract any faster than
n−1/2. This result shows that our posterior contracts at the n−1/2 rate if the product of the contraction
rates for the treatment and outcome model is less than or equal to n−1/2. If the product is larger than
n−1/2 then the posterior of the treatment effect converges at the product of the contraction rates for the
treatment and outcome models. This is a Bayesian analog to results seen in Farrell (2015), and shows
that we can use flexible or high-dimensional models and obtain fast posterior contraction rates due to the
double robustness property. Now, let’s examine the situation when the outcome model does not contract, i.e
sup
P0
EP0Pn( 1√n ||mt −m∗t || < ν1n |D)→ 0 for any ν1 such that ν1n → 0.
sup
P0
EP0Pn(|A3| >
M
4
n|D)
≤ sup
P0
EP0
[
Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31
1√
n
||mt −m∗t ||
|D, 1√
n
||mt −m∗t || < ν1n
)
× Pn
(
1√
n
||mt −m∗t || < ν1n |D
)
+ Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31
1√
n
||mt −m∗t ||
|D, 1√
n
||mt −m∗t || ≥ ν1n
)
× Pn
(
1√
n
||mt −m∗t || ≥ ν1n |D
)]
≤ sup
P0
EP0
[
Pn
(
1√
n
||mt −m∗t || < ν1n |D
)]
+ sup
P0
EP0
[
Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31
1√
n
||mt −m∗t ||
|D, 1√
n
||mt −m∗t || ≥ ν1n
)]
≤ sup
P0
EP0
[
Pn
(
1√
n
||mt −m∗t || < ν1n |D
)]
+ sup
P0
EP0
[
Pn
(
1√
n
||pt − p∗t || >
Mn
4
√
KA31KA32
|D
)]
.
The last inequality holds for some constant 0 < KA32 < ∞ by assumption 2. The first expression goes to
zero since the outcome model is misspecified and does not contract at any rate, while the second expression
converges to zero if the treatment model contracts at rate n. This shows that even if the outcome model
is misspecified, we get contraction of the treatment effect at a rate of either n−1/2 or n, whichever is
larger. This shows both the double robustness property and the contraction rate of the posterior when
only the treatment model is correctly specified. An analogous proof holds for when the treatment model is
misspecified and the outcome model contracts at a given rate, though we leave out the proof as it is nearly
identical to the one above.
Appendix B: Details of posterior sampling
Here we will present the details required for posterior sampling from both the semiparametric and nonpara-
metric priors utilized. Throughout we will denote the full observed data as Di = (Yi, Ti,Xi). First we will
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present the posterior sampling for the semiparametric prior that models the conditional associations between
the treatment/outcome and covariates using splines with d degrees of freedom. We will be always be working
with X being standardized to have mean zero and variance 1, which is crucial when using spike and slab
priors. Throughout, we will show how to estimate the outcome model, but sampling from the treatment
model is analagous with straightforward alterations. Finally, we will be working with the latent outcome
Y ∗i , where in the case of continuous data, Y
∗
i = Yi. If Yi is binary, then at every iteration of our MCMC
we draw Y ∗i from a truncated normal distribution with mean set to β0 + ft(Ti) +
∑p
j=1 fj(Xji) and variance
set to 1. If Yi = 1 then this distribution is truncated below by 0 and if Yi = 0 then it is truncated above by
0. Once we have obtained Y ∗i , then posterior sampling can continue using the latent outcome as if we had
linear regression, even if the outcome is binary.
MCMC sampling for semiparametric prior
Below we detail the full conditional updates for all parameters in the model.
1. If Yi is binary then set σ
2 = 1, and if the outcome is continuous draw σ2 from an inverse-gamma
distribution with parameters a∗ and b∗, defined as:
a∗ = aσ2 +
n
2
+
d
∑p
j=1 γj
2
b∗ = bσ2 +
∑n
i=1
(
Y ∗i − β0 − ft(Ti)−
∑p
j=1 fj(Xji)
)2
2
+
p∑
j=1
d∑
k=1
β2jk
2σ2β
2. While not discussed in the main text, we will be placing a IG(aσ2β , bσ2β) prior on σ2β and therefore we
can update from the full conditional:
σ2β|• ∼ IG
aσ2β + d
∑p
j=1 γj
2
, bσ2β +
p∑
j=1
d∑
k=1
β2jk
2σ2

3. Update θ from the full conditional:
θ|• ∼ B
aθ + p∑
j=1
γj , bθ +
p∑
j=1
(1− γj)

4. To update γj for j = 1 . . . p we need to look at the conditional posterior that has marginalized over
βj . Specifically, if we allow Λ to represent all parameters in the model except for (γj ,βj) then we can
update γj from the following conditional distribution:
p(γj = 1|D,Λ) = p(βj = 0, γj = 1|D,Λ)
p(βj = 0|γj = 1,D,Λ)
=
p(D,Λ|βj = 0, γj = 1)p(βj = 0, γj = 1)
p(D,Λ)p(βj = 0|γj = 1,D,Λ)
=
p(D,Λ|βj = 0)p(βj = 0, γj = 1)
p(D,Λ)p(βj = 0|γj = 1,D,Λ)
∝ p(βj = 0, γj = 1)
p(βj = 0|γj = 1,D,Λ)
=
θ Φ(0; 0,Σβ)
Φ(0;M ,V )
where Φ() represents the multivariate normal density function. M and V represent the conditional
posterior mean and variance for βj when γj = 1 and can be defined as
M =
(
X˜Tj X˜j
σ2
+ Σ−1β
)−1
X˜Tj Y˜ , V =
(
X˜Tj X˜j
σ2
+ Σ−1β
)−1
, (16)
where Y˜ = Y ∗ − β0 − ft(T ) −
∑
k 6=p fk(Xk) and Σβ is a d−dimensional diagonal matrix with σ2σ2β
on the diagonals.
5. For j = 1 . . . p, if γj = 1 update βj from a multivariate normal distribution with mean M and variance
V as defined above. If γj = 0, then set βj = 0.
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6. We will jointly update β0 and ft(T ). For now we will let ft(T ) = βtT , though the full conditional will
take the same form even if we model ft(T ) with polynomials or splines. Define Zt = [1
′,T ], then the
full conditional is of the form
(β0, βt)|• ∼MVN
((
ZTt Zt
σ2
+ Σ−1t
)−1
ZTt Y˜ ,
(
ZTt Zt
σ2
+ Σ−1t
)−1)
where Y˜ = Y ∗ −∑pj=1 fj(Xj) and Σt is a diagonal matrix with K on the diagonals, with K large so
that the treatment effect is not heavily shrunk towards zero.
MCMC sampling with gaussian process priors
Now we will detail the posterior sampling for the model defined in Section 2.2.
1. Update (θ, β0, βt) using the same updates as above for the semiparametric prior specification.
2. To update γj for j = 1 . . . p we need to look at the conditional posterior that has marginalized over
fj(Xj). Specifically, if we allow Λ to represent all parameters in the model except for (γj , fj(Xj)) then
we can update γj from the following conditional distribution:
p(γj = 1|D,Λ) = p(fj(Xj) = 0, γj = 1|D,Λ)
p(fj(Xj) = 0|γj = 1,D,Λ)
=
p(D,Λ|fj(Xj) = 0, γj = 1)p(fj(Xj) = 0, γj = 1)
p(D,Λ)p(fj(Xj) = 0|γj = 1,D,Λ)
=
p(D,Λ|fj(Xj) = 0)p(fj(Xj) = 0, γj = 1)
p(D,Λ)p(fj(Xj) = 0|γj = 1,D,Λ)
∝ p(fj(Xj) = 0, γj = 1)
p(fj(Xj) = 0|γj = 1,D,Λ)
=
θ Φ(0; 0, σ2τ2Σj)
Φ(0;M ,V )
where Φ() represents the multivariate normal density function. M and V represent the conditional
posterior mean and variance for fj(Xj) when γj = 1 and can be defined as
M =
(
In +
1
τ2j
Σ−1j
)−1
Y˜ , V =
(
In +
1
τ2j
Σ−1j
)−1
, (17)
where Y˜ = Y ∗ − β0 − ft(T )−
∑
k 6=p fk(Xk).
3. For j = 1 . . . p, if γj = 1 update fj(Xj) from a multivariate normal distribution with mean M and
variance V as defined above. If γj = 0, then set fj(Xj) = 0.
4. If γj = 0, update τ
2
j from it’s prior distribution, which is a Gamma(1/2, 1/2). If γj = 1, update τ
2
j
from the following distribution:
IG
(
n+ 1
2
,
1
2
+
fj(Xj)
TΣ−1j fj(Xj)
2σ2
)
5. If Yi is binary then set σ
2 = 1, and if the outcome is continuous draw σ2 from an inverse-gamma
distribution with parameters a∗ and b∗ defined as:
a∗ = aσ2 +
n(1 +
∑p
j=1 γj)
2
b∗ = bσ2 +
∑n
i=1
(
Y ∗i − β0 − ft(Ti)−
∑p
j=1 fj(Xji)
)2
2
+
p∑
j=1
γjfj(Xj)
TΣ−1j fj(Xj)
2τ2j
One thing to note is that in the conditional updates for (γj , fj(Xj)), we must calculate
(
In +
1
τ2j
Σ−1j
)−1
,
which means inverting an n by n matrix at every MCMC iteration. To avoid this, we can first compute the
singular value decomposition, Σj = ABA
T , where A is a matrix of eigenvectors and B is a diagonal matrix
of eigenvalues. From this, it can be shown that
(
In +
1
τ2j
Σ−1j
)−1
= A
(
In +
B−1
τ2j
)−1
AT , which only requires
inverting a diagonal matrix and can be computed much faster.
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Appendix C: Implementation of existing approaches
First we will detail how we implement the competing approaches for the linear simulation study. For all
estimators, linear models are assumed, in contrast to our approach that attempts to find the degree of
nonlinearity required. The residual de-biasing approach is implemented using the balanceHD R package,
which is available at github.com/swager/balanceHD. This R package estimates the treatment effect and
provides confidence intervals, with which we perform inference. The TMLE approach is implemented using
the tmle R package (Gruber & van der Laan, 2012). In the super learner library for TMLE, we only included
SL.glmnet, as the true model is contained within this high-dimensional linear model. This package also gives
both estimates and confidence intervals, which is how we performed inference. For the double machine
learning approach, we used sample splitting with K = 5 splits and linear models based on the glmnet
package (Friedman et al. , 2010) for both the treatment and outcome model. We tried fitting the treatment
and outcome model with the output from lasso models, but also attempted fitting both the treatment and
outcome models using post selection estimates of both models. For the post selection estimates, we ran an
initial variable selection step using glmnet, and then fit unpenalized models for both treatment and outcome.
We found that the post selection estimators worked best for the double machine learning approach, and
therefore we present them throughout the paper. We performed inference using the asymptotic standard
errors derived in Chernozhukov et al. (2016). For the double post selection approach, we fit lasso models for
both the treatment and outcome using glmnet with the tuning parameter chosen via cross validation. We
then take the union of the selected variables from the two lasso regressions, and re-fit an unpenalized outcome
regression model using the union of the selected covariates as confounders. Standard errors are calculated
using the asymptotic standard errors derived in Belloni et al. (2014). We used a similar approach to
implementing the lasso-DR approach of Farrell (2015). We fit lasso models using glmnet and cross validation
and identified important covariates for both the treatment and outcome models. Then, given these respective
set of covariates for each model, we fit unpenalized estimates of the outcome and treatment model. These
are then used to estimate the doubly robust estimator described in our manuscript. Inference is again done
using the asymptotic standard errors derived in Farrell (2015).
For the nonlinear simulation section, we restricted attention to TMLE and double machine learning as
these were the most readily available to include nonlinear terms into the model. For both approaches, we ran
an initial variable selection step for both the treatment and outcome model, and then identified important
covariates as those that are in either the treatment or outcome model. For TMLE, we take these covariates
and use the TMLE package with a super learner that includes generalized additive models. Whenever the
model only required linearity, we only included GLM into the super learner to avoid using the overly flexible
models when they are not necessary. For double machine learning, we take the reduced set of covariates and
fit either linear models (when the truth is linear), or nonlinear additive models using spline representations
of the covariates with 3 degrees of freedom. Otherwise, the implementation of the double machine learning
approach is the same as for the linear case.
Appendix D: Illustration of how asymptotics suffer in high-dimensions
In this section we will compare the finite sample and asymptotic variance of our proposed estimator and the
one proposed by Farrell (2015). We will simulate data from sparse, linear models for both the treatment
and outcome. We will apply our doubly robust estimator with Bayesian linear models and sparsity inducing
priors as described in Section 2 of the manuscript. To build a doubly robust estimator, Farrell (2015) fit lasso
(or group lasso) regressions (Tibshirani, 1996; Yuan & Lin, 2006) on both a treatment and outcome model
to identify covariates that are associated with the treatment and outcome respectively. Then, they re-fit
non-penalized estimators of the treatment and outcome models using only the covariates identified by the
original lasso regressions. From these two regressions they can calculate the doubly robust estimator defined
in Equation 3 where pti and mti are estimated using the non-penalized regression models. The authors
derived some important theoretical results that demonstrate that their proposed double robust estimator is
consistent and asymptotically normal. Our goal of this brief illustration is to elucidate why utilizing Bayesian
methods, which do not rely on asymptotics, can provide a more accurate assessment of the finite sample
uncertainty, especially in high-dimensional scenarios. Here we focus on the estimator from Farrell (2015) as it
uses the exact same doubly robust estimator, with the main difference coming in how inference is performed.
As seen in the simulation study of the main manuscript, these ideas extend to other estimators rooted in
asymptotics.
For each of the two doubly robust estimators, we will plot two lines. First, we will show the sampling
distribution of the estimator as taken by the empirical distribution of the estimators across a large number
of simulated datasets. Next, we will plot a normal density centered at the mean of the estimates across all
datasets with a standard deviation that is the average estimated standard error across all datasets. If the
estimated standard errors are correct, then this average standard error should be the same as the standard
deviation of the sampling distribution and the two curves should look similar. 5 shows the results for
n = 100 and p ∈ {100, 300, 500}. The top row shows the results for the estimator based on asymptotic
confidence intervals and the dashed line has much smaller tails than the solid line, indicating that the
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asymptotic distribution used for inference is not properly accounting for the uncertainty in the estimator.
This phenomenon gets worse as p grows larger, and we see that the coverage probabilities decrease from 88%
to 80%. Our approach to the same estimator, however, maintains the correct coverage probabilities for any
dimension of the data, and the dashed and solid lines are very similar, showing that the uncertainty in the
estimator is fully accounted for.
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Figure 5: Comparison of empirical and assumed distributions for the doubly robust
estimator of Farrell (2015) and our approach from Section 2. The solid lines are the
empirical sampling distributions, while the dashed lines are normal distributions with
standard deviation equal to the average estimated standard deviation across the sim-
ulations
Appendix E: Assessing the bootstrap for competing approaches
Here, we will assess whether bootstrapping the competing approaches can provide improved inference over
the asymptotic intervals used in the manuscript. Bootstrapping is justified and has been used for both TMLE
(Schnitzer et al. , 2015) and double machine learning (Knaus, 2018). For the other estimators, it is not clear
whether the standard nonparametric bootstrap would provide valid inference, however, here we will perform
inference using the nonparametric bootstrap for all competing approaches to evaluate whether it provides
better finite sample performance. This is to address the question of whether our approach is only doing
better in finite samples because we are resampling, while the other approaches are not. The results of the
two approaches to inference can be seen in 6.
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Figure 6: The left panel shows the results of the linear simulation study from the
manuscript using asymptotic standard errors for the competing approaches. The right
panel shows the same simulation study with bootstrap based confidence intervals. In
both figures, the Bayes-DR approach uses the approach to inference seen in Section 4
of the manuscript.
In the left panel, we see the results seen in the manuscript that show approaches based on asymptotic
confidence intervals are anti-conservative and obtain confidence interval coverages well below the nominal
level. In the right figure, we see that the bootstrap intervals present the opposite problem. With the
exception of the residual de-biasing approach that achieves low coverages due to large amounts of bias in the
estimator, most estimators have confidence interval coverages at 100% or 99% in the case of the lasso-DR
approach. These intervals are far too wide with average estimated standard errors well above two times the
standard error of the estimators. This indicates that these intervals are extremely conservative and lead to
confidence intervals that are far too wide. This is due to the erratic nature of the bootstrapped estimators
in small samples when variable selection is involved in the estimation procedure.
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Figure 7: Results from the linear simulation study with n = 400 and p = 50. The left
panel shows the results using asymptotic standard errors for the competing approaches.
The right panel shows the same simulation study with bootstrap based confidence
intervals. In both figures, the Bayes-DR approach uses the approach to inference seen
in Section 4 of the manuscript.
To assess whether these approaches to inference correct themselves as the sample size increases, we tried
the same test, but with n = 400 and p = 50. The results can be seen in 7. We see that when we are in
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a scenario with a larger sample size and more favorable p/n ratio that both methods to inference provide
interval coverages very close to the nominal level for all approaches considered.
Appendix F: Additional simulation scenario
Here we will run an identical simulation to the linear simulation scenario from the manuscript with n = 100
and p = 500, however, we will change the data generating models to see if the performance of the various
approaches we saw in the manuscript holds for other scenarios as well. Now, we will generate data from the
following treatment and outcome models:
µi = Ti + 0.45X1i + 0.7X2i − 0.6X3i + 1.3X4i − 0.5X5i
pi = Φ(0.35X1i + 0.2X2i − 0.3X3i − 0.4X5i)
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Figure 8: Results from the additional simulation scenario. The left panel presents the
mean squared error, while the right panel presents the 95% interval coverages.
The results of this simulation study can be seen in 8. We see that the proposed approach does very well
in terms of MSE, and is only beaten in terms of MSE by the TMLE estimator. Most notably, however, all of
the existing approaches based on asymptotic confidence intervals show coverage probabilities far below the
95% level. Our approach appears to be accounting for more of the finite sample uncertainty in the estimation
of the causal effect, which leads to a much higher coverage rate. All of the estimators in this scenario had a
non-negligible amount of bias and therefore none of the approaches obtain interval coverages of 95%. While
not shown here, we again tried to use bootstrapping approaches to fix the problems with undercoverage, and
we found erratic confidence intervals from the bootstrap that were far too wide and led to 100% coverages
for the competing approaches.
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